- Home
- CLPT vs CBIO Comparison
CLPT vs CBIO Comparison
Compare CLPT & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPT
- CBIO
- Stock Information
- Founded
- CLPT 1998
- CBIO 2003
- Country
- CLPT United States
- CBIO United States
- Employees
- CLPT N/A
- CBIO N/A
- Industry
- CLPT Medical/Dental Instruments
- CBIO
- Sector
- CLPT Health Care
- CBIO
- Exchange
- CLPT Nasdaq
- CBIO Nasdaq
- Market Cap
- CLPT 317.4M
- CBIO 308.0M
- IPO Year
- CLPT N/A
- CBIO N/A
- Fundamental
- Price
- CLPT $10.49
- CBIO $14.29
- Analyst Decision
- CLPT Strong Buy
- CBIO Strong Buy
- Analyst Count
- CLPT 3
- CBIO 5
- Target Price
- CLPT $27.67
- CBIO $25.60
- AVG Volume (30 Days)
- CLPT 375.5K
- CBIO 98.3K
- Earning Date
- CLPT 08-12-2025
- CBIO 07-31-2025
- Dividend Yield
- CLPT N/A
- CBIO N/A
- EPS Growth
- CLPT N/A
- CBIO N/A
- EPS
- CLPT N/A
- CBIO N/A
- Revenue
- CLPT $33,593,000.00
- CBIO N/A
- Revenue This Year
- CLPT $22.34
- CBIO N/A
- Revenue Next Year
- CLPT $25.50
- CBIO N/A
- P/E Ratio
- CLPT N/A
- CBIO N/A
- Revenue Growth
- CLPT 19.68
- CBIO N/A
- 52 Week Low
- CLPT $9.76
- CBIO $10.83
- 52 Week High
- CLPT $19.22
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- CLPT 44.46
- CBIO 52.92
- Support Level
- CLPT $10.42
- CBIO $13.50
- Resistance Level
- CLPT $10.88
- CBIO $16.00
- Average True Range (ATR)
- CLPT 0.52
- CBIO 0.79
- MACD
- CLPT -0.01
- CBIO 0.16
- Stochastic Oscillator
- CLPT 22.75
- CBIO 39.68
About CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.